For the twelve months ended Jun 30, 2026, Valion Bio Inc. reported -$18.75M of net income.
VBIO revenue was $146.0K in fiscal Q3 2025 (ended Sep 30, 2025), up 15.9% from a year earlier and up 69.8% from the prior quarter. For the full fiscal 2024 it was $780.0K, down 33.7% from fiscal 2023. It rose in 1 of the last 3 fiscal years.
VBIO net income was -$7.10M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.93M a year earlier. For the full fiscal 2025 it was -$8.88M, compared with -$5.66M in fiscal 2024.
VBIO diluted EPS was -$2.19 in fiscal Q2 2025 (ended Jun 30, 2025). For the full fiscal 2024 it was -$19.68.
VBIO free cash flow was -$5.34M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.83M a year earlier. For the full fiscal 2025 it was -$7.04M, compared with -$5.72M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | - | $780.0K | $1.18M | $1.84M | $1.26M |
| Cost of revenue | - | $778.0K | $889.0K | $1.54M | $1.29M |
| Gross profit | - | $2.0K | $287.0K | $299.0K | -$38.0K |
| Research and development | $3.13M | $1.31M | $1.66M | $1.73M | $878.0K |
| Selling, general and admin | $4.77M | $3.16M | $4.75M | $5.88M | $2.93M |
| Operating income | -$7.90M | -$4.48M | -$8.24M | -$10.10M | -$5.63M |
| Interest expense | $146.0K | $0 | - | - | - |
| Pre-tax income | - | - | -$8.24M | -$10.10M | - |
| Income tax | $0 | $0 | - | - | - |
| Net income | -$8.88M | -$5.66M | -$8.24M | -$10.10M | -$8.49M |
| EPS, basic | -$7.84 | -$19.68 | -$176.80 | -$1773.44 | -$4131.00 |
| EPS, diluted | - | -$19.68 | -$176.80 | -$1773.44 | -$4131.00 |
| Diluted shares | - | 287,370 | 46,650 | 5,692.824 | 2,054.863 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $12.64M | $2.00M | $3.40M | $3.52M | $12.97M |
| Receivables | - | $69.0K | $174.0K | $107.0K | $92.0K |
| Inventory | $0 | $319.0K | $756.0K | $863.0K | $429.0K |
| Current assets | $13.01M | $2.64M | $4.65M | $5.31M | $14.29M |
| Goodwill | $3.46M | $0 | - | - | - |
| Total assets | $31.61M | $2.81M | $5.16M | $5.88M | $15.04M |
| Current liabilities | $646.0K | $272.0K | $1.40M | $1.88M | $1.22M |
| Total liabilities | $7.44M | $272.0K | $1.58M | $2.25M | $1.76M |
| Shareholders' equity | $16.80M | $2.54M | $3.58M | $3.63M | $13.27M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.00M | -$5.72M | -$8.51M | -$8.92M | -$5.61M |
| Capital expenditures | $38.0K | $0 | $118.0K | $11.0K | - |
| Free cash flow | -$7.04M | -$5.72M | -$8.63M | -$8.93M | - |
| Investing cash flow | -$705.0K | $0 | -$118.0K | -$11.0K | - |
| Financing cash flow | $18.35M | $4.33M | $8.51M | -$528.0K | $17.54M |
| Stock-based compensation | $564.0K | $229.0K | $271.0K | $398.0K | $57.0K |
| Depreciation and amortization | - | $3.0K | $8.0K | $10.0K | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | - | -33.7% | -36.1% | 46.4% | - |
| Gross margin | - | 0.3% | 24.4% | 16.3% | -3.0% |
| Operating margin | - | -573.8% | -701.1% | -548.8% | -448.1% |
| Net margin | - | -725.0% | -701.0% | -548.7% | -675.7% |
| Free cash flow margin | - | -734.0% | -733.8% | -485.3% | - |
| Return on equity | -52.9% | -223.1% | -230.3% | -278.1% | -64.0% |
| Return on assets | -28.1% | -201.5% | -159.9% | -171.8% | -56.5% |
| Current ratio | 20.13 | 9.70 | 3.32 | 2.83 | 11.72 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $146.0K | $86.0K | $70.0K | $180.0K | $126.0K | $140.0K | $334.0K | $357.0K | $282.0K |
| Cost of revenue | - | - | - | $291.0K | $32.0K | $20.0K | $419.0K | $82.0K | $110.0K | $167.0K | $352.0K | $174.0K |
| Gross profit | - | - | - | -$145.0K | $54.0K | $50.0K | -$239.0K | $44.0K | $30.0K | $167.0K | $5.0K | $108.0K |
| Research and development | $2.70M | $1.85M | $1.28M | $858.0K | $655.0K | $335.0K | $333.0K | $422.0K | $302.0K | $256.0K | $360.0K | $337.0K |
| Selling, general and admin | $3.72M | $3.78M | $1.75M | $1.06M | $1.02M | $1.04M | $670.0K | $819.0K | $787.0K | $887.0K | $1.15M | $1.05M |
| Operating income | -$6.42M | -$5.63M | -$1.98M | -$2.48M | -$1.68M | -$1.38M | -$298.0K | -$1.43M | -$1.27M | -$1.48M | -$2.24M | -$1.76M |
| Interest expense | $691.0K | $648.0K | - | - | $0 | $0 | - | - | - | - | - | - |
| Net income | -$7.10M | -$6.20M | -$2.85M | -$2.60M | -$1.93M | -$1.50M | -$1.48M | -$1.43M | -$1.27M | -$1.48M | -$2.24M | -$1.76M |
| EPS, basic | -$2.17 | -$2.23 | - | -$1.97 | -$2.19 | -$2.52 | - | -$3.93 | -$5.37 | -$17.15 | - | -$25.16 |
| EPS, diluted | - | - | - | - | -$2.19 | -$2.52 | - | -$3.91 | -$5.37 | -$17.15 | - | -$25.16 |
| Diluted shares | - | - | - | - | 881,294 | 596,368 | - | 364,183.941 | 235,868 | 86,338 | - | 69,989.471 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.11M | $7.21M | $12.64M | $3.45M | $1.18M | $669.0K | $2.00M | $2.19M | $3.69M | $1.67M | $3.40M | $5.17M |
| Receivables | - | - | - | $19.0K | $13.0K | $13.0K | $69.0K | $9.0K | $16.0K | $74.0K | $174.0K | $131.0K |
| Inventory | $750.0K | $750.0K | $0 | $4.0K | $283.0K | $306.0K | $319.0K | $731.0K | $766.0K | $774.0K | $756.0K | $928.0K |
| Current assets | $3.38M | $8.65M | $13.01M | $3.74M | $1.84M | $1.26M | $2.64M | $3.16M | $4.66M | $2.83M | $4.65M | $6.46M |
| Goodwill | $3.46M | $3.46M | $3.46M | - | - | - | $0 | - | - | - | - | - |
| Total assets | $32.47M | $38.22M | $31.61M | $6.23M | $4.51M | $3.78M | $2.81M | $3.39M | $4.78M | $3.29M | $5.16M | $7.01M |
| Current liabilities | $3.05M | $2.62M | $646.0K | $638.0K | $821.0K | $741.0K | $272.0K | $560.0K | $591.0K | $992.0K | $1.40M | $1.00M |
| Total liabilities | $20.59M | $19.67M | $7.44M | $638.0K | $821.0K | $741.0K | $272.0K | $560.0K | $591.0K | $1.13M | $1.58M | $1.24M |
| Shareholders' equity | $4.25M | $11.06M | $16.80M | $3.41M | $3.69M | $3.04M | $2.54M | $2.83M | $4.19M | $2.15M | $3.58M | $5.76M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.28M | -$5.01M | -$2.29M | -$2.00M | -$1.83M | -$889.0K | -$1.36M | -$1.41M | -$1.29M | -$1.67M | -$1.77M | -$1.87M |
| Capital expenditures | $57.0K | $7.0K | $25.0K | $10.0K | $3.0K | $0 | $0 | - | - | - | $0 | $0 |
| Free cash flow | -$5.34M | -$5.02M | -$2.31M | -$2.01M | -$1.83M | -$889.0K | -$1.36M | - | - | - | -$1.77M | -$1.87M |
| Investing cash flow | -$57.0K | -$7.0K | -$149.0K | -$10.0K | -$20.0K | -$526.0K | $0 | - | - | - | $0 | $0 |
| Financing cash flow | $231.0K | -$44.0K | $11.63M | $4.27M | $2.36M | $82.0K | $1.18M | -$97.0K | $3.31M | -$61.0K | $0 | $4.38M |
| Stock-based compensation | $133.0K | $208.0K | $149.0K | $139.0K | $176.0K | $100.0K | $63.0K | $58.0K | $54.0K | $54.0K | $58.0K | $48.0K |
| Depreciation and amortization | - | - | - | - | $1.0K | $1.0K | $0 | $1.0K | $1.0K | $1.0K | $2.0K | $1.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | 15.9% | -38.6% | -79.0% | -49.6% | -55.3% | -13.0% | -11.2% | -12.5% | -40.9% |
| Gross margin | - | - | - | -99.3% | 62.8% | 71.4% | -132.8% | 34.9% | 21.4% | 50.0% | 1.4% | 38.3% |
| Operating margin | - | - | - | -1700.7% | -1951.2% | -1967.1% | -165.6% | -1135.7% | -904.3% | -443.4% | -628.6% | -624.1% |
| Net margin | - | - | - | -1778.1% | -2245.3% | -2145.7% | -820.6% | -1135.7% | -904.3% | -443.4% | -628.3% | -624.1% |
| Free cash flow margin | - | - | - | -1374.0% | -2127.9% | -1270.0% | -758.3% | - | - | - | -496.9% | -663.5% |
| Current ratio | 1.11 | 3.31 | 20.13 | 5.86 | 2.24 | 1.70 | 9.70 | 5.65 | 7.89 | 2.85 | 3.32 | 6.46 |
Source: XBRL data Valion Bio Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-100, first reported Nov 14, 2023; 1-for-17, first reported Mar 21, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VBIO | - | - | -$18.75M | - | $1.1M |
| MDT | $37.54B | +9.8% | $5.24B | 14.0% | $129.18B |
| LIVN | $1.51B | +11.7% | $196.06M | 13.0% | $4.97B |
| ITGR | $1.83B | -0.3% | $103.70M | 5.7% | $4.30B |
| AXGN | $266.93M | +24.3% | -$31.92M | -12.0% | $3.31B |
| TMDX | $727.65M | +28.5% | $144.45M | 19.9% | $3.20B |
| CNMD | $1.37B | +1.6% | $73.43M | 5.4% | $1.50B |
| CBLL | $108.72M | +31.3% | -$73.88M | -68.0% | $1.02B |
| INMD | $370.50M | -6.2% | $93.83M | 25.3% | $758.2M |